Naomi Kresge

Novo Nordisk A/S’s sales of blockbuster weight-loss drug Wegovy beat expectations in the third quarter, a potential relief for investors after rival Eli Lilly & Co.’s disappointing obesity sales last week.

Novo Nordisk A/S's sales of the blockbuster weight-loss drug Wegovy leapt last quarter as it became available in more countries, a relief for investors after rival Eli Lilly & Co. reported disappointing obesity sales last week.

Danish biotech Gubra A/S said its experimental obesity drug showed weight loss and mild side effects in a small study, clearing a crucial early hurdle.

Eisai Co. and its partners won the European Union regulator’s backing for use of its Alzheimer’s drug Leqembi in a surprising reversal of a previously negative opinion.

Roche Holding AG is extremely optimistic that its latest experimental Alzheimer's drug will deliver a benefit for patients, Chief Executive Officer Thomas Schinecker said, despite a track record of failures in the field.

About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater access to its human insulin and lower prices, while also protesting against the Danish company’s recent decision to phase out easy-to-use pens to deliver the diabetes medication.

Hi, this is Naomi in Berlin, where the season of gingerbread and chocolate will soon threaten to reprogram everyone’s cells. More on that soon, but first...

Novartis AG raised its medium-term sales guidance, citing upbeat expectations for new cancer and immunological disease medicines, as well as treatments for neurological and cardiovascular conditions.

Drugmaker sees revenue growing 6% per year through to 2029

Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the rush to add capacity for blockbuster drugs Ozempic and Wegovy.